




Searching News Database: Orexigen Therapeutics
HSMN NewsFeed - 23 Jun 2023
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 7 Jun 2016
Sanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary
Sanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary
HSMN NewsFeed - 18 Oct 2013
Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors
Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors
HSMN NewsFeed - 29 Jun 2011
Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer
Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer
HSMN NewsFeed - 17 Feb 2011
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
HSMN NewsFeed - 1 Feb 2011
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
HSMN NewsFeed - 5 Dec 2008
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
HSMN NewsFeed - 10 Mar 2008
OREXIGEN(TM) Therapeutics Appoints Carol Baum as Vice President of Commercialization
OREXIGEN(TM) Therapeutics Appoints Carol Baum as Vice President of Commercialization
HSMN NewsFeed - 11 Dec 2007
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
HSMN NewsFeed - 17 Oct 2007
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
HSMN NewsFeed - 24 May 2006
OREXIGEN(TM) Therapeutics Appoints Graham Cooper as Chief Financial Officer
OREXIGEN(TM) Therapeutics Appoints Graham Cooper as Chief Financial Officer
Additional items found! 4

Members Archive contains
4 additional stories matching:
Orexigen Therapeutics
(Password required)
Orexigen Therapeutics
(Password required)